These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29180684)

  • 41. Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans.
    Wang C; Huo X; Wang C; Meng Q; Liu Z; Sun P; Cang J; Sun H; Liu K
    J Pharm Sci; 2017 Sep; 106(9):2515-2523. PubMed ID: 28535976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease.
    Leithold LH; Jiang N; Post J; Niemietz N; Schartmann E; Ziehm T; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
    Eur J Pharm Sci; 2016 Jun; 89():31-8. PubMed ID: 27086111
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.
    Brown HS; Wilby AJ; Alder J; Houston JB
    Drug Metab Dispos; 2010 Dec; 38(12):2139-46. PubMed ID: 20847136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
    Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
    Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.
    Ribeiro CA; Oliveira SM; Guido LF; Magalhães A; Valencia G; Arsequell G; Saraiva MJ; Cardoso I
    J Alzheimers Dis; 2014; 39(2):357-70. PubMed ID: 24169237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Associations Between Hepatic Functions and Plasma Amyloid-Beta Levels-Implications for the Capacity of Liver in Peripheral Amyloid-Beta Clearance.
    Wang YR; Wang QH; Zhang T; Liu YH; Yao XQ; Zeng F; Li J; Zhou FY; Wang L; Yan JC; Zhou HD; Wang YJ
    Mol Neurobiol; 2017 Apr; 54(3):2338-2344. PubMed ID: 26957302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease.
    Hirsch-Reinshagen V; Wellington CL
    Curr Opin Lipidol; 2007 Jun; 18(3):325-32. PubMed ID: 17495608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease.
    Xiang Y; Bu XL; Liu YH; Zhu C; Shen LL; Jiao SS; Zhu XY; Giunta B; Tan J; Song WH; Zhou HD; Zhou XF; Wang YJ
    Acta Neuropathol; 2015 Oct; 130(4):487-99. PubMed ID: 26363791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease.
    Tschiffely AE; Schuh RA; Prokai-Tatrai K; Prokai L; Ottinger MA
    Horm Behav; 2016 Jul; 83():39-44. PubMed ID: 27210479
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes.
    Fukuda H; Ohashi R; Tsuda-Tsukimoto M; Tamai I
    Drug Metab Dispos; 2008 Jul; 36(7):1275-82. PubMed ID: 18388177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.
    Toyama H; Ye D; Ichise M; Liow JS; Cai L; Jacobowitz D; Musachio JL; Hong J; Crescenzo M; Tipre D; Lu JQ; Zoghbi S; Vines DC; Seidel J; Katada K; Green MV; Pike VW; Cohen RM; Innis RB
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):593-600. PubMed ID: 15791432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
    Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
    Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
    Strelevitz TJ; Orozco CC; Obach RS
    Drug Metab Dispos; 2012 Jul; 40(7):1441-8. PubMed ID: 22522748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aluminum may mediate Alzheimer's disease through liver toxicity, with aberrant hepatic synthesis of ceruloplasmin and ATPase7B, the resultant excess free copper causing brain oxidation, beta-amyloid aggregation and Alzheimer disease.
    Brenner S
    Med Hypotheses; 2013 Mar; 80(3):326-7. PubMed ID: 23261179
    [No Abstract]   [Full Text] [Related]  

  • 56. Oxidation of R(+)- and S(-)-carvedilol by rat liver microsomes. Evidence for stereoselective oxidation and characterization of the cytochrome P450 isozymes involved.
    Fujimaki M
    Drug Metab Dispos; 1994; 22(5):700-8. PubMed ID: 7835220
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice.
    Wang HC; Zhang T; Kuerban B; Jin YL; Le W; Hara H; Fan DS; Wang YJ; Tabira T; Chui DH
    Neurosci Bull; 2015 Aug; 31(4):491-504. PubMed ID: 26254061
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of diclofenac in rhesus monkeys.
    Prueksaritanont T; Li C; Tang C; Kuo Y; Strong-Basalyga K; Carr B
    Drug Metab Dispos; 2006 Nov; 34(11):1806-10. PubMed ID: 16928785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
    Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
    Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.